PMVP Valuation

PMV Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.230

-0.02(-1.600%)1D

Overview
Forecast
Valuation
Earnings

PMVP Relative Valuation

PMVP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PMVP is overvalued; if below, it's undervalued.

Historical Valuation

PMV Pharmaceuticals Inc (PMVP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.38. The fair price of PMV Pharmaceuticals Inc (PMVP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.21

Fair

-0.85

Trailing

Forward

0.00

EV/EBITDA

PMV Pharmaceuticals Inc. (PMVP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -6.42. The thresholds are as follows: Strongly Undervalued below -27.70, Undervalued between -27.70 and -17.06, Fairly Valued between 4.22 and -17.06, Overvalued between 4.22 and 14.85, and Strongly Overvalued above 14.85. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.88

EV/EBIT

PMV Pharmaceuticals Inc. (PMVP) has a current EV/EBIT of 0.88. The 5-year average EV/EBIT is -6.23. The thresholds are as follows: Strongly Undervalued below -28.12, Undervalued between -28.12 and -17.18, Fairly Valued between 4.71 and -17.18, Overvalued between 4.71 and 15.66, and Strongly Overvalued above 15.66. The current Forward EV/EBIT of 0.88 falls within the Historic Trend Line -Fairly Valued range.

0.00

PMV Pharmaceuticals Inc. (PMVP) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

PMV Pharmaceuticals Inc. (PMVP) has a current P/OCF of 0.00. The 5-year average P/OCF is -8.37. The thresholds are as follows: Strongly Undervalued below -32.93, Undervalued between -32.93 and -20.65, Fairly Valued between 3.90 and -20.65, Overvalued between 3.90 and 16.18, and Strongly Overvalued above 16.18. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.77

P/FCF

PMV Pharmaceuticals Inc. (PMVP) has a current P/FCF of -0.77. The 5-year average P/FCF is -6.64. The thresholds are as follows: Strongly Undervalued below -27.24, Undervalued between -27.24 and -16.94, Fairly Valued between 3.67 and -16.94, Overvalued between 3.67 and 13.97, and Strongly Overvalued above 13.97. The current Forward P/FCF of -0.77 falls within the Historic Trend Line -Fairly Valued range.

PMV Pharmaceuticals Inc (PMVP) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.78 , the current P/B ratio is approximately -39.60% higher. Relative to its 5-year average P/B ratio of 1.92, the current P/B ratio is about -75.41% higher. PMV Pharmaceuticals Inc (PMVP) has a Forward Free Cash Flow (FCF) yield of approximately -110.30%. Compared to its 3-year average FCF yield of -52.87%, the current FCF yield is approximately 108.64% lower. Relative to its 5-year average FCF yield of -33.48% , the current FCF yield is about 229.45% lower.

0.47

P/B

Median3y

0.78

Median5y

1.92

-110.30

FCF Yield

Median3y

-52.87

Median5y

-33.48

Competitors Valuation Multiple

The average P/S ratio for PMVP's competitors is 0.00, providing a benchmark for relative valuation. PMV Pharmaceuticals Inc Corp (PMVP) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PMVP.O

PMV Pharmaceuticals Inc

Mink Therapeutics Inc

Loss

64.41M

KLRS.O

Kalaris Therapeutics Inc

Prelude Therapeutics Inc

Loss

58.86M

COEP.O

Coeptis Therapeutics Holdings Inc

Loss

60.74M

Performance Decomposition

Market capitalization of PMVP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PMVP in the past 1 year is driven by Unknown.